Otometrics Returns: Natus Sensory Revives a Legacy Brand for Future Growth

SCHAUMBURG, IL – April 22, 2026 – In a significant strategic move, Natus Sensory Inc. today announced the revival of the Otometrics brand, a name that resonates deeply with hearing and balance professionals globally. The decision positions Otometrics as the parent brand for the company’s entire Hearing & Balance solutions portfolio, unifying a suite of well-known diagnostic tools under a single, trusted banner.

This restoration is more than a simple name change; it represents a deliberate effort to reconnect with a legacy of clinical trust while signaling a focused strategy for future innovation. All existing products, including the renowned Madsen® audiometers, Aurical® fitting systems, and ICS® vestibular diagnostics, will now be part of 'Otometrics, a division of Natus Sensory.'

“The Otometrics brand has a strong heritage in our industry, and bringing it back reflects both where we come from and where we are going,” said Peter Reimer, CEO of Natus Sensory, in a statement. “We are building on a trusted foundation while investing in new innovations that will support clinicians and improve patient outcomes across hearing and balance care.”

A Strategic Return to a Trusted Legacy

For many audiologists and vestibular specialists, the Otometrics name is synonymous with reliability and innovation. Before being acquired by Natus Medical Incorporated in a $145 million deal that closed in early 2017, Otometrics was widely considered the world's largest developer of hearing and balance assessment equipment. Its products were staples in clinics, universities, and hospitals, forming the backbone of diagnostic and fitting procedures.

The integration into the larger Natus Medical structure meant the Otometrics name gradually faded from the forefront, even as its core technologies continued to evolve. The brand's restoration under the newly independent Natus Sensory—which began operating in January 2025—is a clear acknowledgment of the powerful brand equity that has endured. By resurrecting a name clinicians already know and respect, the company aims to reinforce its commitment to the specific needs of the audiology community and create a more cohesive identity in a crowded marketplace.

This move consolidates a powerful portfolio. From the Madsen audiometers used for comprehensive hearing tests to the Aurical systems that are critical for hearing aid fitting and verification, and the ICS line that provides gold-standard vestibular diagnostics, these tools will now share a unified identity. This not only simplifies branding but also promises a more integrated user experience, particularly through software platforms like Otosuite, which connects the various devices into a single diagnostic workflow.

Reshaping the Competitive Landscape

The decision to revive Otometrics is a calculated maneuver within the highly competitive and consolidated audiology devices market. This global market, estimated at over $14 billion in 2024 and projected to exceed $20 billion by the early 2030s, is dominated by a handful of major players. Companies like Sonova, Demant (which owns key competitor Interacoustics), and GN Store Nord command a significant majority of the market share, leveraging extensive distribution networks and massive R&D budgets.

In this environment, brand differentiation and focused strategy are paramount. By separating its Hearing & Balance portfolio under the distinct Otometrics brand, Natus Sensory is drawing a clear line around its expertise in this specific segment. This allows the company to tailor its messaging, product development, and support directly to audiologists and balance specialists, rather than diluting its identity within a broader medical device framework. The company's Newborn Care portfolio, featuring established brands like ALGO® and RetCam®, will continue to be marketed separately under the Natus Sensory name, underscoring this deliberate segmentation.

This strategic sharpening is a direct outcome of Natus Sensory's new status as an independent entity, a change driven by its owner, the healthcare-focused investment firm ARCHIMED. This new structure is designed to make the company more agile and responsive to its core markets.

The ARCHIMED Effect and a Renewed Focus

The revival of Otometrics cannot be understood without considering the influence of ARCHIMED. The investment firm acquired the publicly traded Natus Medical in a $1.1 billion take-private deal in 2022. ARCHIMED's leadership identified the strength of Natus's distinct business units and initiated a strategic separation, creating two specialized companies: Natus Sensory and Natus Neuro.

This restructuring allows each company to concentrate its resources and expertise. For Natus Sensory, it has unlocked a period of accelerated growth and strategic action. The firm's investment thesis centers on reinforcing R&D, expanding global reach, and pursuing targeted growth—all of which are reflected in the Otometrics rebranding. It is a classic private equity play: take a strong asset, trim away non-core distractions, and invest heavily to dominate a specific niche.

Recent activities confirm this aggressive strategy. In the past year, Natus Sensory has appointed new executive leadership, including a Chief Commercial Officer and a Chief Financial Officer, to steer its expansion. It has also forged a key distribution partnership with Oaktree Products to broaden market access in the U.S. and made strategic acquisitions to bolster its Newborn Care division. The Otometrics brand restoration is the most visible component of this broader, well-funded campaign to re-establish a leadership position in sensory diagnostics.

Innovation on the Horizon: What This Means for Clinicians

Beyond the strategic and financial implications, the most pressing question for clinicians is what this change means for the tools they use every day. The company has been clear that this move is about more than just marketing, promising a robust “pipeline of new Otometrics developments planned for 2026 and beyond.”

While specific details remain under wraps, the direction of innovation can be inferred from recent product launches and prevailing industry trends. The launch of the ICS Dizcovery VNG solution in the U.S. in 2025 demonstrates an ongoing commitment to advancing vestibular diagnostics. Future developments are likely to focus on greater integration between devices, leveraging the Otosuite software to create a seamless ecosystem for patient data management from initial assessment to treatment verification.

Clinicians can anticipate advancements that incorporate trends like AI-powered analytics for more precise diagnostics, enhanced teleaudiology features for remote patient care, and improved workflow efficiencies that save time in a busy clinic. The unification under the Otometrics banner should foster deeper integration between hearing assessment (Madsen), hearing aid fitting (Aurical), and balance testing (ICS), potentially enabling new diagnostic pathways and more holistic patient care.

As the industry gathers for major events like the American Academy of Audiology (AAA) Annual Convention this week, all eyes will be on the Natus Sensory booth to see the newly revitalized Otometrics brand in action. The return of this legacy name is not just a nod to the past but a bold declaration of intent for the future of hearing and balance care.